|
AU2010314395B2
(en)
|
2009-11-05 |
2015-04-09 |
Glaxosmithkline Llc |
Benzodiazepine bromodomain inhibitor
|
|
EP3050885B1
(en)
|
2009-11-05 |
2017-10-18 |
GlaxoSmithKline LLC |
Benzodiazepine bromodomain inhibitor
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
EP2571875A4
(en)
|
2010-05-14 |
2013-10-30 |
Dana Farber Cancer Inst Inc |
CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
|
|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
JP5844358B2
(ja)
|
2010-06-22 |
2016-01-13 |
グラクソスミスクライン エルエルシー |
ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
|
|
WO2012075456A1
(en)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Bromodomain inhibitors and uses thereof
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
US9422292B2
(en)
|
2011-05-04 |
2016-08-23 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
US9624244B2
(en)
|
2012-06-06 |
2017-04-18 |
Constellation Pharmaceuticals, Inc. |
Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
JP2016510039A
(ja)
*
|
2013-02-28 |
2016-04-04 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
HUE043568T2
(hu)
|
2013-03-14 |
2019-08-28 |
Glaxosmithkline Ip No 2 Ltd |
2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
|
|
SG11201506924YA
(en)
|
2013-03-15 |
2015-09-29 |
Incyte Corp |
Tricyclic heterocycles as bet protein inhibitors
|
|
US9393232B2
(en)
|
2013-04-26 |
2016-07-19 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
JP6461118B2
(ja)
|
2013-06-21 |
2019-01-30 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規の置換された二環式化合物
|
|
SI3010503T1
(sl)
|
2013-06-21 |
2020-07-31 |
Zenith Epigenetics Ltd. |
Novi biciklični inhibitorji bromodomene
|
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
US9975896B2
(en)
|
2013-07-25 |
2018-05-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
RU2016122654A
(ru)
|
2013-11-08 |
2017-12-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
CN105980392A
(zh)
*
|
2013-12-10 |
2016-09-28 |
艾伯维公司 |
溴区结构域抑制剂
|
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
CN105940005A
(zh)
|
2014-01-31 |
2016-09-14 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
|
EP3099677A4
(en)
|
2014-01-31 |
2017-07-26 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
JP2017506666A
(ja)
|
2014-02-28 |
2017-03-09 |
テンシャ セラピューティクス，インコーポレイテッド |
高インスリン血症に関連した症状の処置
|
|
PL3134403T3
(pl)
|
2014-04-23 |
2020-07-13 |
Incyte Corporation |
1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
|
|
PL3157928T3
(pl)
|
2014-06-20 |
2019-07-31 |
Constellation Pharmaceuticals, Inc. |
Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
|
|
CN106715437A
(zh)
|
2014-08-08 |
2017-05-24 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
|
CN106793775B
(zh)
|
2014-08-08 |
2020-06-02 |
达纳-法伯癌症研究所股份有限公司 |
二氢碟啶酮衍生物及其用途
|
|
BR112017004580A2
(pt)
|
2014-09-12 |
2018-01-23 |
GlaxoSmithKline Intellectual Property |
composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
|
|
JP6599979B2
(ja)
|
2014-09-15 |
2019-10-30 |
インサイト・コーポレイション |
Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
CN107709314A
(zh)
|
2015-06-11 |
2018-02-16 |
巴斯利尔药物国际股份公司 |
外排泵抑制剂及其治疗性用途
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
US20180193350A1
(en)
|
2015-06-26 |
2018-07-12 |
Tensha Therapeutics, Inc. |
Treatment of nut midline carcinoma
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
EP3347021A4
(en)
|
2015-09-11 |
2019-07-24 |
Dana-Farber Cancer Institute, Inc. |
CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
|
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
MX2018006499A
(es)
|
2015-11-25 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos.
|
|
EP3464270B1
(en)
|
2016-05-24 |
2022-02-23 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
|
|
CA3028689A1
(en)
|
2016-06-20 |
2017-12-28 |
Incyte Corporation |
Crystalline solid forms of a bet inhibitor
|
|
WO2018111805A1
(en)
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN114751836B
(zh)
*
|
2021-02-23 |
2024-05-31 |
四川青木制药有限公司 |
3-(4-甲基-1h-咪唑-1-基)-5-(三氟甲基)苯胺合成方法及其中间体
|
|
WO2023205251A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|